Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. reported a significant year-over-year revenue increase of 18%, reaching $483 million, while providing guidance for peak sales exceeding $1 billion, with projected revenue of $1 billion in 2029. The company's growth strategy includes expanding the depth and breadth of prescribing for its products, particularly through ongoing clinical trials such as the Phase 3 trial for IBSRELA, which could enhance revenue potential. Additionally, XPHOZAH demonstrated strong performance with a 41% increase in ex-Medicare business in 2025 and a 9% overall year-over-year growth in dispenses, further supported by investments in patient assistance programs and targeted prescriber engagement.

Bears say

Ardelyx Inc. faces significant financial challenges, as evidenced by their projected 1Q26 revenue for Ibsrela, which anticipates an 18% quarter-over-quarter decline despite an expected annual total of $422 million. The company's peak sales guidance of over $1 billion appears unachievable, compounded by concerns over reimbursement pricing structures and the risk of not acquiring essential product labeling features that could enhance market traction. Furthermore, the reported net loss of $0.4 million for 4Q25 and low patient adherence rates to phosphate binder treatment underscore potential difficulties in sustaining growth and securing necessary capital for ongoing operations.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.